Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 2, 2017, Pages 83-85

  Nauck, Michael A ^a   Meier, Juris J ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN DERIVATIVE;

DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MULTICENTER STUDY (TOPIC); NOTE; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULINS; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE;

EID: 85007578414     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30401-6     Document Type: Note

References (11)

1. 1 Pomposelli, JJ, Baxter, JK 3rd, Babineau, TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 22 (1998), 77–81.
2. 2 Ramos, M, Khalpey, Z, Lipsitz, S, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 248 (2008), 585–591.
3. 3 Breuer, TG, Meier, JJ, Inpatient treatment of type 2 diabetes. Dtsch Arztebl Int 109 (2012), 466–474.
4. 4 Umpierrez, GE, Smiley, D, Zisman, A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 30 (2007), 2181–2186.
5. 5 Umpierrez, GE, Hellman, R, Korytkowski, MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97 (2012), 16–38.
6. 6 Krinsley, JS, Grover, A, Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 35 (2007), 2262–2267.
7. 7 Turchin, A, Matheny, ME, Shubina, M, Scanlon, JV, Greenwood, B, Pendergrass, ML, Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 32 (2009), 1153–1157.
8. 8 Pasquel, FJ, Gianchandani, R, Rubin, DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital.): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol, 2016 published online Dec 7. http://dx.doi.org/10.1016/S2213-8587(16)30402-8.
9. 9 Arnolds, S, Dellweg, S, Clair, J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33 (2010), 1509–1515.
10. 10 Meier, JJ, Pennartz, C, Schenker, N, et al. Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy. Diabetes Obes Metab 15 (2013), 258–263.
11. 11 McAlister, FA, Man, J, Bistritz, L, Amad, H, Tandon, P, Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care 26 (2003), 1518–1524.